```
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       149.75     149.96

FILE 'CAPLUS' ENTERED AT 12:05:31 ON 29 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 29 Jan 2003  VOL 138 ISS 5
FILE LAST UPDATED: 28 Jan 2003  (20030128/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l3
L4          17 L3

=> s l17 and (ru or ruthenium)
L17 NOT FOUND
The L-number entered could not be found.  To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l4 and (ru or ruthenium)
         54648 RU
         69870 RUTHENIUM
L5           3 L4 AND (RU OR RUTHENIUM)

=> d bib abs 1-3

L5   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2003 ACS
AN   2002:778057  CAPLUS
DN   137:294761
TI   Chemical bond forming reactions using .alpha.-halocarbonyl compounds and
     transmetalation reagents.
IN   Zhang, Xumu; Lei, Aiwen
PA   The Penn State Research Foundation, USA
SO   PCT Int. Appl., 35 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     --------------    ----  --------       ---------------  --------
PI   WO 2002079339      A2   20021010       WO 2002-US9623   20020329
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
```

TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002193543 A1 20021219 US 2002-108420 20020329
PRAI US 2001-280275P P 20010330
OS CASREACT 137:294761
AB A method of forming a chem. bond comprises combining .gtoreq.1 .alpha.-halocarbonyl compd. with .gtoreq.1 transmetalation reagent comprising a target compd., and forming a chem. bond to or within the target compd. The transmetalation reagents are formed by the addn. of a metal or metal catalyst to a target compd. The target compd. is the compd. undergoing chem. bond formation. Bond formation can be carried out in both intermol. or intramol. reactions. Thus, reaction of 3,5-dimethylphenylboronic acid in the presence of Pd2(dba)3.CHCl3, rac-BINAP, and KF in dioxane gave 97% 3,3',5,5'-tetramethylbiphenyl.

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 1999:753145 CAPLUS
DN 132:13300
TI Catalytic asymmetric hydrogenation and hydroformylation via transition metal complex catalysts with chiral phosphine or phosphite ligands
IN Zhang, Xumu
PA The Penn State Research Foundation, USA
SO PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9959721	A1	19991125	WO 1999-US10907	19990518

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, DE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6207868	B1	20010327	US 1998-190155	19981112
AU 9949521	A1	19991206	AU 1999-49521	19990518
US 6278024	B1	20010821	US 2000-524787	20000313
US 6399787	B1	20020604	US 2000-685028	20001010
US 2001047113	A1	20011129	US 2001-878417	20010612
US 6380416	B2	20020430		
PRAI US 1998-85786P	P	19980518		
US 1998-90164P	P	19980622		
US 1997-876120	A2	19970613		
US 1997-65577P	P	19971112		
US 1998-190155	A3	19981112		
US 1999-313665	B3	19990518		
WO 1999-US10907	W	19990518		
US 2000-524787	A3	20000313		

OS MARPAT 132:13300
AB Transition metal catalysts with conformationally rigid chiral phosphines and phosphites are developed for asym. C-H and C-C bond formation. Chiral amines, .beta.-amino acids, and related compds. are synthesized via catalytic asym. hydrogenation based on chiral monodentate and bidentate phosphines with cyclic ring structures.
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 1999:120265 CAPLUS
DN 130:281548
TI **Ru**-BICP-Catalyzed asymmetric hydrogenation of aromatic ketones
AU Cao, Ping; Zhang, Xumu
CS Department of Chemistry, The Pennsylvania State University, University Park, PA, 16802, USA
SO Journal of Organic Chemistry (1999), 64(6), 2127-2129
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 130:281548
GI



I

AB A **Ru**-BICP [BICP = R,R-bis(diphenylphosphino)bicyclopentyl I] catalyst system was prepd. and was effective in the asym. hydrogenation of arom. ketones ArCOMe (Ar = Ph, 2-naphthyl, 2-thienyl, etc.). Thus, hydrogenation of 4-FC6H4COMe in Me2CHOH contg. RuCl2[(R,R)-BICP](TMEDA) [TMEDA = tetramethylethylenediamine], (R,R)-1,2-diphenylethylenediamine, and KOH gave (S)-4-FC6H4CHMeOH with 100% conversion and 74% enantiomeric excess.
RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s l4 not l5
L6 14 L4 NOT L5

=> s l6 and diphosphi?
8882 DIPHOSPHI?
L7 5 L6 AND DIPHOSPHI?

=> s l7 and diamin?
125696 DIAMIN?
L8 0 L7 AND DIAMIN?

=> s l6 and diamin?
125696 DIAMIN?
L9 2 L6 AND DIAMIN?

=> d bib abs l7 1-5

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 1999:429228 CAPLUS
DN 131:170395
TI Stereoselective preparation of phosphine oxides via a 2,3-sigmatropic shift of allylic diphenylphosphinites
AU Demay, Stephane; Harms, Klaus; Knochel, Paul

CS Fachbereich Chemie der Ludwig Maximilians-Universitat, Munchen, D-81377, Germany
SO Tetrahedron Letters (1999), 40(27), 4981-4984
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 131:170395
GI



I



II

AB The thermic rearrangement of various chiral or racemic allylic diphenylphosphinites, e.g. I (n = 0, 1; R = H, Me) to allylic phosphine oxides II has been applied for the prepn. of several chiral **diphosphine** oxides of interest for asym. catalysis.
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 1999:325945 CAPLUS
DN 130:338252
TI Catalysts for asymmetric syntheses containing rigid chiral ligands
IN Zhang, Xumu
PA The Pennsylvania State University, USA
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9924443	A2	19990520	WO 1998-US24037	19981112
	WO 9924443	A3	19990520		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6037500	A	20000314	US 1997-876120	19970613
	CA 2309193	AA	19990520	CA 1998-2309193	19981112
	AU 9913982	A1	19990531	AU 1999-13982	19981112
	EP 1030854	A2	20000830	EP 1998-957814	19981112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

	BR 9814638	A	20001003	BR 1998-14638	19981112
	US 6207868	B1	20010327	US 1998-190155	19981112
	JP 2001522854	T2	20011120	JP 2000-520452	19981112
	US 6278024	B1	20010821	US 2000-524787	20000313
	US 6399787	B1	20020604	US 2000-685028	20001010
	US 2001047113	A1	20011129	US 2001-878417	20010612
	US 6380416	B2	20020430		
PRAI	US 1997-876120	A	19970613		
	US 1997-65577P	P	19971112		
	US 1996-19938P	P	19960614		
	US 1996-33493P	P	19961220		
	US 1997-46121P	P	19970509		
	US 1998-85786P	P	19980518		
	US 1998-90164P	P	19980622		
	US 1998-190155	A3	19981112		
	WO 1998-US24037	W	19981112		
	US 1999-313665	B3	19990518		
	US 2000-524787	A3	20000313		

OS CASREACT 130:338252

GI



I

AB This invention is to develop novel transition metal catalysts for the practical synthesis of important chiral mols. The invention emphasizes asym. catalysis based on chiral bidentate phosphine ligands with cyclic ring structures which could be used to restrict conformational flexibility of the ligands and thus the efficiency of chiral transfer can be enhanced through the ligand rigidity. Thus, reductive coupling of cyclopentanone with Al powder in the presence of HgCl2 catalyst in C6H6 gave 1,1'-dihydroxy-1,1'-dicyclopentyl which on dehydration with POCl3 in pyridine gave 1,1'-dicyclopentyl. Asym. redn. of 1,1'-dicyclopentyl followed by mesylation, phosphination, and sequential deborylation gave title compd., e.g. I. [Rh(COD)2]BF4-I catalyzed asym. hydrogenation of .alpha.-acetamidocinnamic acid gave hydrogenated product up to 96.1% enantiomeric excess depending upon the solvent used.

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 1998:13970 CAPLUS
DN 128:102242
TI Asymmetric synthesis catalyzed by transition metal complexes with cyclic chiral ligands
IN Zhang, Xumu
PA Penn State Research Foundation, USA
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9747633	A1	19971218	WO 1997-US10436	19970613

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,

DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

	CA 2258018	AA	19971218	CA 1997-2258018	19970613
	AU 9733971	A1	19980107	AU 1997-33971	19970613
	CN 1225095	A	19990804	CN 1997-196420	19970613
	BR 9709790	A	19990810	BR 1997-9790	19970613
	IL 127397	A1	20011223	IL 1997-127397	19970613
	JP 2002513376	T2	20020508	JP 1998-501886	19970613
	KR 2000016597	A	20000325	KR 1998-710193	19981212
PRAI	US 1996-19938P	P	19960614		
	US 1996-33493P	P	19961220		
	US 1997-46121P	P	19970509		
	WO 1997-US10436	W	19970613		

OS CASREACT 128:102242
GI



I



II

AB The present invention relates to rigid chiral ligands useful in making catalysts for asym. synthesis. More particularly, the present invention relates to new monodentate and bidentate cyclic chiral phosphine ligands which are formed into catalysts to provide high selectivity of the enantiomeric structure of the end-product. Thus, asym. hydroboration of 1,1'-dicyclopentene with (+)-monoisopinocamphenylborane [(+)-IpcBH2] followed by oxidn. with H2O2 gave the diol which was converted to chiral **diphosphine** ligand I. [Rh(COD)2]BF4-catalyzed asym. hydrogenation of .alpha.-acetamidocinnamic acid in the presence of ligand I gave satd. acid II in 96.8% enantiomeric excess.

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 1997:148799 CAPLUS
DN 126:211870
TI Highly Enantioselective Rh-Catalyzed Hydrogenations with a New Chiral 1,4-**Diphosphine** Containing a Cyclic Backbone
AU Zhu, Guoxin; Cao, Ping; Jiang, Qiongzhong; Zhang, Xumu
CS Department of Chemistry, Pennsylvania State University, University Park, PA, 16802, USA
SO Journal of the American Chemical Society (1997), 119(7), 1799-1800
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
GI



I

AB The new bisphosphine I, having all 4 chiral centers R, was prepd. and found to be an excellent ligand for Rh(I)-catalyzed asym. hydrogenation of .alpha.-(acylamino)acrylic acids. The high enantioselectivity achieved with I may stem from its conformational rigidity.

L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 1977:11412 CAPLUS
DN 86:11412
TI Ditertiary (phosphines and arsines) with perfluoro(bi-1-cycloalken-1-yl) bridging groups. Preparation and properties including a solid state structure of a tetracarbonylmolybdenum derivative
AU Cullen, William R.; Wu, Anthony W.; Davis, Alan R.; Einstein, Frederick W. B.; Hazlett, John D.
CS Chem. Dep., Univ. British Columbia, Vancouver, BC, Can.
SO Canadian Journal of Chemistry (1976), 54(18), 2871-8
CODEN: CJCHAG; ISSN: 0008-4042
DT Journal
LA English
GI



I



V

AB The perfluorobi-1-cycloalken-1-yl dichlorides react with arsines and phosphines, R2EH, to yield I (n = 2, R2E = (Me)2As, II; n = 2, R2E = (Ph)2P, III; n = 3, R2E = (Me)2As, IV; and V, where R = PPh2). Methyl diphenylphosphinate affords V, where R = P(O)Ph2. The ditertiary phosphine III is photochromic in the solid state. It reacts with M(CO)6 (M = Cr, Mo, W) to give (L-L)M(CO)4. Similar compds. are obtained from the ditertiary arsines II and IV. The solid state structure of the Mo(CO)4 deriv. of IV was detd. from 3-dimensional single-crystal data. The compd. crystallizes in the orthorhombic space group Pbcn with a 16.26(1), b 11.55(1), c 13.34(1) .ANG., and there are 4 mols. in the unit cell. The coordinates of the heavy atoms were detd. by vector space methods. All other at. parameters were obtained by full matrix least-squares refinement to a final R factor of 10.1% for 715 reflections. The ligand is chelated to the Mo atom and the resulting 7-membered ring is considerably puckered. The As-Mo-As angle is 89.6(0.2).degree..

=> d bib abs l9 1-2

L9 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 2002:803342 CAPLUS
TI Highly Enantioselective Ag(I)-Catalyzed [3 + 2] Cycloaddition of Azomethine Ylides
AU Longmire, James M.; Wang, Bin; Zhang, Xumu

CS Department of Chemistry, Pennsylvania State University, University Park, PA, 16802, USA
SO Journal of the American Chemical Society (2002), 124(45), 13400-13401
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
GI



I

AB A highly reactive Ag(I)-catalyzed [3 + 2] cycloaddn. of azomethine ylides is founded using AgOAc as the catalytic precursor and phosphines as ligands. Using a new bis-ferrocenyl amide phosphine (FAP) as the ligand, the authors found that high enantioselectivities (up to 97% ee) have been achieved in the [3 + 2] cycloaddn. of azomethine ylides, generated from imines RCH:NCH2CO2Me (R = Ph, 4-MeOC6H4, Me2CH, etc.), with dipolarophiles, e.g. di-Me maleate, Me acrylate, and N-methylmaleimide, giving pyrrolidines I (R = Ph, 1-naphthyl, cyclohexyl, etc.). Up to four stereogenic centers can be established in this multicomponent coupling reaction from readily available materials such as aldehydes, aminoesters, and dipolarophiles.
RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 2001:597876 CAPLUS
DN 135:180880
TI Chiral ferrocene phosphines and their use in asymmetric catalytic reactions
IN Zhang, Xumu
PA The Penn State Research Foundation, USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001058588	A1	20010816	WO 2001-US4442	20010209
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002091280	A1	20020711	US 2001-781083	20010209
	EP 1257360	A1	20021120	EP 2001-909127	20010209
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRAI US 2000-181448P P 20000210
US 2000-214167P P 20000626
WO 2001-US4442 W 20010209
OS CASREACT 135:180880; MARPAT 135:180880
AB Metal complexes with ferrocene anchored chiral ligands are useful in asym. catalysis, such as hydrogenation and allylic alkylation. Thus, (S,S,S,S)ferrocene amide phosphine was prepd. from (1S,2S)-**diaminocyclohexane** and chiral carboxyferrocenyl di-Ph phosphine and used in combination with (.eta.3-allyl)PdCl2 to catalysis allylic alkylation between 2-cyclohexenyl acetate and di-Me malonate to give [(1R)-2-cyclohexen-1-yl]propanedioic acid di-Me ester in 61% and 20% ee (R).
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT



```
ENTER (DIS), GRA, NOD, BON OR ?:end
L1   STRUCTURE CREATED

=> s l1
SAMPLE SEARCH INITIATED 11:46:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     23 TO ITERATE

100.0% PROCESSED      23 ITERATIONS                                  5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          173 TO      747
PROJECTED ANSWERS:               5 TO      234

L2            5 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 11:46:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    274 TO ITERATE

100.0% PROCESSED     274 ITERATIONS                                 35 ANSWERS
SEARCH TIME: 00.00.01

L3           35 SEA SSS FUL L1

=> d scan

L3   35 ANSWERS   REGISTRY  COPYRIGHT 2003 ACS
IN   1-Propanone, 1-[3,5-difluoro-4-(phenylmethoxy)phenyl]-2-[4-hydroxy-4-[4-
     (trifluoromethyl)phenyl]-1-piperidinyl]- (9CI)
MF   C28 H26 F5 N O3
```



```
=> s l3
L4          16 L3

=> s l4 and (ru or ruthenium)
         54648 RU
         69870 RUTHENIUM
L5           0 L4 AND (RU OR RUTHENIUM)

=> s l4 and diphosph?
         62468 DIPHOSPH?
L6           0 L4 AND DIPHOSPH?

=> s l4 and diamin?
        125696 DIAMIN?
L7           0 L4 AND DIAMIN?

=> s l4 and hydrogena?
        243188 HYDROGENA?
L8           0 L4 AND HYDROGENA?

=> d bib abs l4 9-16

L4   ANSWER 9 OF 16  CAPLUS  COPYRIGHT 2003 ACS
AN   1997:377705  CAPLUS
DN   126:343494
TI   Treatment of tinnitus using (hydroxyphenyl)piperidinylpropanols and
     analogs as neuroprotective agents
IN   Sands, Stephen B.
PA   Pfizer Inc., USA
SO   Eur. Pat. Appl., 16 pp.
     CODEN: EPXXDW
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   EP 768086          A1   19970416       EP 1996-306198   19960827
     EP 768086          B1   20020925
         R:  AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
     TW 450807          B    20010821       TW 1996-85107025 19960611
     AT 224714          E    20021015       AT 1996-306198   19960827
     JP 3038155         B2   20000508       JP 1996-262343   19960912
     CA 2185512         AA   19970316       CA 1996-2185512  19960913
     AU 9665635         A1   19970320       AU 1996-65635    19960913
     AU 697679          B2   19981015
     CN 1149454         A    19970514       CN 1996-112326   19960913
PRAI US 1995-3855P      P    19950915
OS   MARPAT 126:343494
GI
```



I









II

AB Title compds. I [R1-R4 = H, alkyl, halo, CF3, OH, OR7; R5 = Me, Et; or R2R5 = OCH2 and R1, R3, R4 = H, alkyl, halo, CF3, OH, OR7; R6 = aza(bi)cycloalkyl groups Q1, Q2, or Q3; R7 = Me, Et, Pr, iso-Pr; R8 = Ph (un)substituted by 0-3 of alkyl, halo, CF3; X = O, S, (CH2)n; n = 0-3], and their pharmaceutically acceptable salts, are neuroprotective agents, specifically NMDA antagonists, useful in the treatment of tinnitus (no data). Several compds., notably II, its enantiomer, and their tartrate salts, were prepd. Examples include resolns. of racemates, and a large-scale synthetic prepn.

L4 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2003 ACS
AN 1997:262327 CAPLUS
DN 126:238309
TI Preparation of (1S, 2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate as an NMDA antagonist.
IN Andino, Marta M.; Sinay, Terry G.; Fiese, Eugene F.
PA Pfizer Inc., USA; Andino, Marta M.; Sinay, Terry G.; Fiese, Eugene F.
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9707098	A1	19970227	WO 1996-IB592	19960620
W: AU, BG, BR, BY, CA, CN, CZ, HU, IL, IS, JP, KR, KZ, LK, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2228752	AA	19970227	CA 1996-2228752	19960620
AU 9659084	A1	19970312	AU 1996-59084	19960620
AU 710984	B2	19991007		
EP 843661	A1	19980527	EP 1996-916266	19960620
EP 843661	B1	20020327		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LV				

	JP 10510552	T2	19981013	JP 1996-509083	19960620
	CN 1198739	A	19981111	CN 1996-195649	19960620
	RU 2140910	C1	19991110	RU 1998-102116	19960620
	JP 3099072	B2	20001016	JP 1997-509083	19960620
	IL 122649	A1	20010826	IL 1996-122649	19960620
	AT 215072	E	20020415	AT 1996-916266	19960620
	ES 2170857	T3	20020816	ES 1996-916266	19960620
	NO 9800574	A	19980210	NO 1998-574	19980210
	US 6008233	A	19991228	US 1998-11426	19980507
	BR 9610766	A	19990713	BR 1996-10766	19980511
PRAI	US 1995-2238P	P	19950811		
	WO 1996-IB592	W	19960620		

AB Title compd. (I) was prepd. for treatment of degenerative nervous disorders (no data). Thus, 4'-benzyloxypropiophenone (prepn. given) was stirred with Br in CH2Cl2 to give 77.6% .alpha.-bromo deriv., which was refluxed with 4-hydroxy-4-phenylpiperidine and Et3N in EtOAc to give 77% 4-hydroxy-4-phenyl-1-[1-(4-benzyloxybenzoyl)ethyl]piperidine. The latter was reduced with NaBH4 in EtOH to give 86.5% threo alc. deriv., which was hydrogenolyzed (90%), resolved with D-tartaric acid, converted to the free base, and salified with MeSO3H in H2O to give I.

L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2003 ACS
AN 1997:97184 CAPLUS
DN 126:104016
TI Preparation of 1-hydroxyphenyl-2-hydroxypiperidinopropanols and analogs as NMDA antagonists
IN Chenard, Bertrand L.; Menniti, Frank S.
PA Pfizer Inc., USA; Chenard, Bertrand, L.; Menniti, Frank, S.
SO PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9637226	A2	19961128	WO 1995-IB398	19950526
	WO 9637226	A3	19961227		
	W: CA, FI, JP, MX, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2219911	AA	19961128	CA 1995-2219911	19950526
	EP 828513	A2	19980318	EP 1995-918111	19950526
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
	JP 11505828	T2	19990525	JP 1995-535520	19950526
	RU 2176145	C2	20011127	RU 1996-109832	19950526
	TW 470740	B	20020101	TW 1996-85105153	19960430
	IL 118328	A1	20001206	IL 1996-118328	19960520
	NO 9602130	A	19961127	NO 1996-2130	19960524
	AU 9654519	A1	19961205	AU 1996-54519	19960524
	AU 696258	B2	19980903		
	CN 1159325	A	19970917	CN 1996-107556	19960524
	ZA 9604180	A	19971124	ZA 1996-4180	19960524
	BR 9602485	A	19980422	BR 1996-2485	19960527
	CZ 283979	B6	19980715	CZ 1996-1524	19960527
	US 6258827	B1	20010710	US 1997-930599	19971010
	FI 9704323	A	19971125	FI 1997-4323	19971125
PRAI	HU 1996-1419	A	19960524		
	CA 1995-2219911	A	19950526		
	WO 1995-IB398	W	19950526		

OS MARPAT 126:104016
GI



AB Title compds. [I; R1-R4 = H, halo, alkyl, alkoxy, etc.; R5 = Me or Et; R2R5 = OCH2; R6 = 4-hydroxy-4-phenylpiperidino, 3-hydroxy-3-phenylpyrrolidino, azabicycloalkyl group Q, etc.; R8 = (un)substituted Ph; Z = bond, O, S, (CH2)1-3] were prepd. as NMDA antagonists (no data). Thus, 3-fluoro-4-triisopropylsilyloxy-.alpha.-bromopropiophenone (prepn. given) was aminated by 4-(4-fluorophenyl)-4-hydroxypiperidine and the product reduced to give, after deprotection, title compd. II.

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2003 ACS
AN 1997:70358 CAPLUS
DN 126:157399
TI Method for treating spinal cord trauma with phenolic 2-piperidino-1-alkanols
IN Chenard, Bertrand L.
PA Pfizer Inc., USA
SO U.S., 8 pp., Cont.-in-part of U.S. 5, 455, 250.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5594007	A	19970114	US 1994-195797	19940214
	US 5455250	A	19951003	US 1993-119122	19930916
	US 5654302	A	19970805	US 1995-418713	19950407
	US 5696126	A	19971209	US 1995-418718	19950407
PRAI	US 1991-687273		19910418		
	US 1993-119122		19930916		
	WO 1992-US2131		19920324		

OS MARPAT 126:157399
GI For diagram(s), see printed CA Issue.
AB Title compds. I [R = H, C1-6 alkyl, C2-6 alkenyl or alkynyl; X = (substituted) Ph, PhCH2, PhO, C1-3 alkoxy; E completes a substituted piperidino or pyrrolidino ring], useful for blocking N-methyl-D-aspartic acid (NMDA) receptor sitess in a mammal (no data) were prepd. by std. chem. Thus, coupling 4-(morpholinomethyl)benzoic acid with 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanone with EDC and DMAP in CH2Cl2 and then redn. with NaBH4 in EtOH gave racemic I [R = Me, X = 4-(morpholinomethyl)phenyl; ester attached at 4-position; 4-hydroxy-4-phenylpiperidino].

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2003 ACS
AN 1996:404653 CAPLUS
DN 125:86500
TI Preparation of neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives
IN Chenard, Bertrand L.; Butler, Todd W.
PA Pfizer Inc., USA
SO PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9606081	A1	19960229	WO 1995-IB380	19950518
	W: AU, CA, CN, CZ, FI, HU, JP, KR, MX, NO, NZ, PL, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2197451	AA	19960229	CA 1995-2197451	19950518
	AU 9523511	A1	19960314	AU 1995-23511	19950518
	AU 684359	B2	19971211		
	EP 777652	A1	19970611	EP 1995-917443	19950518
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1155279	A	19970723	CN 1995-194643	19950518
	JP 09509189	T2	19970916	JP 1995-507895	19950518
	JP 2888988	B2	19990510		
	HU 77520	A2	19980528	HU 1997-2051	19950518
	RU 2139857	C1	19991020	RU 1997-102362	19950518
	IL 114892	A1	20000716	IL 1995-114892	19950810
	BR 9503694	A	19960528	BR 1995-3694	19950817
	US 6046213	A	20000404	US 1997-776715	19970213
	FI 9700664	A	19970217	FI 1997-664	19970217
	NO 9700728	A	19970217	NO 1997-728	19970217
PRAI	US 1994-292651	A	19940818		
	WO 1995-IB380	W	19950518		

OS MARPAT 125:86500
GI



I

AB The title compds. [I; R1-R4 = H, alkyl, halogen, CF3, OH, etc; R5 = Me, ethyl; R6 = (un)substituted piperidino, (un)substituted pyrrolidino, etc.; R2R5 = OCH2; etc.], useful for treating stroke (no data), spinal cord trauma (no data), traumatic brain injury (no data), multiinfarct dementia (no data), CNS degenerative diseases such as Alzheimer's disease (no data), etc. (no data), are prepd. Thus, 3-fluoro-4-trisopropylsilyloxy-.alpha.-bromopropiophenone was reacted with 4-(4-fluorophenyl)-4-hydroxypiperidine, the intermediate reduced with NaBH4, and the free base salified with MeSO3H, producing, (1R,2R)-1-(3-fluoro-4-hydroxyphenyl)-2-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl]propan-1-ol mesylate, m.p. 239-241.degree..

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2003 ACS
AN 1995:699265 CAPLUS

DN 123:285708
TI (1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: A Potent New Neuroprotectant Which Blocks N-Methyl-D-Aspartate Responses
AU Chenard, B. L.; Bordner, J.; Butler, T. W.; Chambers, L. K.; Collins, M. A.; De Costa, D. L.; Ducat, M. F.; Dumont, M. L.; Fox, C. B.; et al.
CS Central Research Division, Pfizer Inc., Groton, CT, 06340, USA
SO Journal of Medicinal Chemistry (1995), 38(16), 3138-45
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB (+)-4-Hydroxy-.alpha.-(4-hydroxyphenyl)-.beta.-methyl-4-phenyl-1-piperidinethanol (CP-101,606) was identified as a potent and selective N-methyl-D-aspartate (NMDA) antagonist through a structure activity relation (SAR) program based on ifenprodil, a known antihypertensive agent with NMDA antagonist activity. Sites on the threo-ifenprodil skeleton explored in this report include the pendent Me group (H, Me, and Et nearly equipotent; Pr much weaker), the spacer group connecting the C-4 Ph group to the piperidine ring (an alternating potency pattern with 0 and 2 carbon atoms yielding the greatest potency), and simple Ph substitution (little effect). While potent NMDA antagonists were obtained with a two atom spacer, this arrangement also increased .alpha.1 adrenergic affinity. Introduction of a hydroxyl group into the C-4 position on the piperidine ring resulted in substantial redn. in .alpha.1 adrenergic affinity. The combination of these observations was instrumental in the discovery of CP-101,606 . This compd. potently protects cultured hippocampal neurons from glutamate toxicity (IC50 = 10 nM) while possessing little of the undesired .alpha.1 adrenergic affinity (IC50 .apprx. 20 .mu.M) of ifenprodil. Furthermore, CP-101,606 appears to lack the psychomotor stimulant effects of nonselective competitive and channel-blocking NMDA antagonists. Thus, CP-101,606 shows great promise as a neuroprotective agent and may lack the side effects of compds. currently in clin. trials.

L4 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2003 ACS
AN 1993:495538 CAPLUS
DN 119:95538
TI Prodrug esters of phenolic 2-piperidino-1-alkanols
IN Chenard, Bertrand L.
PA Pfizer Inc., USA
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9218502	A1	19921029	WO 1992-US2131	19920324
	W: AU, BR, CA, CS, DE, FI, HU, JP, KR, NO, PL, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	CA 2108557	AA	19921019	CA 1992-2108557	19920324
	AU 9217839	A1	19921117	AU 1992-17839	19920324
	AU 654554	B2	19941110		
	JP 06501022	T2	19940127	JP 1992-509961	19920324
	JP 07088355	B4	19950927		
	EP 584192	A1	19940302	EP 1992-911061	19920324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	HU 65836	A2	19940728	HU 1993-2928	19920324
	BR 9205893	A	19941108	BR 1992-5893	19920324
	CN 1065866	A	19921104	CN 1992-102845	19920416
	ZA 9202811	A	19931018	ZA 1992-2811	19920416
	US 5455250	A	19951003	US 1993-119122	19930916
	NO 9303723	A	19931015	NO 1993-3723	19931015
PRAI	US 1991-687273		19910418		

WO 1992-US2131 19920324

OS MARPAT 119:95538

GI For diagram(s), see printed CA Issue.

AB Title compds. I [E = (CH2)2CY2Y3(CH2)2, (CH2)2CY2Y3CH2, CH2CH2CY9:CHCH2; R = H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl; X = Ph, CH2Ph, C1-3 alkoxy, OPh, aforementioned group substituted by R1R2N(CH2)p; p = 1, 2; R1,R2 = H, C1-6 alkyl or NR1R2 = pyrrolidinyl, piperidinyl, or morpholinyl ring, aforementioned ring substituted by C1-3 alkyl; Y2Y3 = Q1 or Y2 = OH and Y3 = Q2; Y9 = Q2; n = 0-3; m = 0-4; Q = S, CH:CH; X1 = H, C1-3 alkyl, C1-3 alkoxy, halo] and related compds. are prodrugs useful in the treatment of stroke, traumatic head injury and CNS degenerative disease (no data). Thus, esterification of 4-(morpholinomethyl)benzoic acid by 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanone in CH2Cl2 contg. 4-Me2NC5H4N and EtN:C:N(CH2)3NMe2.HCl, followed by NaBH4 redn. of the intermediate ketone gave title compd. II as a mixt. of isomers.

L4 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2003 ACS

AN 1991:408584 CAPLUS

DN 115:8584

TI Preparation of 2-piperidino-1-alkanol derivatives as antiischemic agents

IN Chenard, Bertrand Leo

PA Pfizer Inc., USA

SO Eur. Pat. Appl., 48 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 398578	A2	19901122	EP 1990-304975	19900509
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	SK 279476	B6	19981104	SK 1990-2328	19890517
	CZ 284342	B6	19981014	CZ 1990-2328	19900511
	US 5185343	A	19930209	US 1991-784446	19911023
	US 5272160	A	19931221	US 1992-932844	19920820
	US 5338754	A	19940816	US 1993-96913	19930723
	US 5391742	A	19950221	US 1994-228466	19940415
	US 5710168	A	19980120	US 1994-336639	19941109
	US 5527912	A	19960618	US 1995-411030	19950327
PRAI	WO 1989-US2176	A	19890517		
	WO 1990-US292	A	19900116		
	US 1991-784446	A3	19911023		
	US 1992-932844	A3	19920820		
	US 1993-96913	A3	19930723		
	US 1994-228466	A2	19940415		
	US 1994-336639	A3	19941109		

OS MARPAT 115:8584

GI



I

II



III

AB The title compds. (I; R = H, alkyl, alkenyl, alkynyl; X = H, OH, aryl; Y = H, OH; Y1 = aryl, aralkyl, arylthio, aryloxy, YY1 = arylmethylene, aralkylmethylene; Q = S, CH:CH), useful as antiischemic agents in treating strokes, Alzheimer's disease, Huntington's disease, and Parkinson's disease (no data), are prepd. A mixt. of piperidine deriv. II, p-(Me2CH)3SiOC6H4COCHBrMe, and Et3N in EtOH was refluxed to give 23% propiophenone III, which was reduced with LiAlH4 to give 89% mixt. of (1R*,2S*)- and (1S*,2S*)-I [R = Me, X = 4-(Me2CH)3SiO, YY1 = PhCH, Q = CH:CH] (IV). Hydrolysis of IV with Bu4N+ F- in THF at room temp. gave the mixt. phenolic alc. (1S*,2S*)- and (1R*,2S*)-I (R = Me, X = 4-HO, YY1 = PhCH, Q = CH:CH). Also prepd. were 75 addnl. I and intermediates.

=> d bib l4 1-8

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2003 ACS
AN 2002:314393 CAPLUS
DN 136:325428
TI Preparation of 1-(hydroxyphenyl)-2-(phenylpiperidinyl)-1-propanol NMDA NR2B antagonists for treating depression and neurodegenerative disorders
IN Chenard, Bertrand Leo; Menniti, Frank Samuel; Saltarelli, Mario David
PA Pfizer Products Inc., USA
SO Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1199068	A2	20020424	EP 2001-308295	20010928
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	AU 2001077304	A5	20020411	AU 2001-77304	20010928
	JP 2002161052	A2	20020604	JP 2001-306254	20011002
	US 2002072538	A1	20020613	US 2001-969317	20011002
PRAI	US 2000-237770P	P	20001002		

OS MARPAT 136:325428

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2003 ACS
AN 2002:314392 CAPLUS
DN 136:319415
TI N-methyl-D-aspartate antagonists for prophylactic and treatment in a mammal of neurol. damage resulting from impairment of glucose and/or oxygen supply to the brain
IN Chenard, Bertrand Leo; Menniti, Frank Samuel; Saltarelli, Mario David; Schneider, Erika
PA Pfizer Products Inc., USA

SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1199067	A2	20020424	EP 2001-308289	20010928
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002072485	A1	20020613	US 2001-969354	20011002
JP 2002322092	A2	20021108	JP 2001-306332	20011002
PRAI US 2000-237324P	P	20001002		

OS MARPAT 136:319415

L4 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2003 ACS
AN 2002:183752 CAPLUS
DN 136:241682
TI Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
IN Chenard, Bertrand Leo; Saltarelli, Mario David; Menniti, Frank Samuel
PA Pfizer Products Inc., USA
SO Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1186304	A2	20020313	EP 2001-307521	20010904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002123510	A1	20020905	US 2001-947878	20010906
JP 2002322096	A2	20021108	JP 2001-270308	20010906
PRAI US 2000-230943P	P	20000906		

OS MARPAT 136:241682

L4 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2003 ACS
AN 2002:183751 CAPLUS
DN 136:226803
TI Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
IN Chenard, Bertrand Leo; Menniti, Frank Samuel; Saltarelli, Mario David
PA Pfizer Products Inc., USA
SO Eur. Pat. Appl., 28 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1186303	A2	20020313	EP 2001-307246	20010824
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2001003888	A	20020604	BR 2001-3888	20010905
US 2002045656	A1	20020418	US 2001-947652	20010906
JP 2002322095	A2	20021108	JP 2001-270196	20010906
PRAI US 2000-230944P	P	20000906		

OS MARPAT 136:226803

L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2003 ACS
AN 2001:796279 CAPLUS

DN 135:331349
TI Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol and its intermediates
IN Rainville, Joseph Philip; Sinay, Terry Gene, Jr.; Walinsky, Stanley Walter
PA Pfizer Products Inc., USA
SO Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1149831	A1	20011031	EP 2001-303713	20010424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002016466	A1	20020207	US 2001-840668	20010423
CA 2345286	AA	20011028	CA 2001-2345286	20010426
BR 2001001611	A	20020115	BR 2001-1611	20010426
CN 1322716	A	20011121	CN 2001-117154	20010427
JP 2001354650	A2	20011225	JP 2001-130684	20010427

PRAI US 2000-200417P P 20000428
OS CASREACT 135:331349; MARPAT 135:331349
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2003 ACS
AN 2001:508068 CAPLUS
DN 135:87188
TI Method using a NR2B-selective NMDA antagonist for treating acute, chronic and/or neuropathic pain
IN Menniti, Frank S.; Chenard, Bertrand L.; Saltarelli, Mario D.; Parker, Jonathon M.
PA USA
SO U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2001007872	A1	20010712	US 1999-397891	19990917

PRAI US 1998-102630P P 19981001
OS MARPAT 135:87188

L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2003 ACS
AN 1998:118605 CAPLUS
DN 128:167356
TI Preparation of phenylpiperidinylpropanols as neuroprotectants for treatment of tinnitus.
IN Sands, Steven B.
PA Pfizer Inc., USA
SO U.S., 10 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5716961	A	19980210	US 1996-709996	19960909

PRAI US 1996-709996 19960909
OS MARPAT 128:167356